
After a quarter of a century of rapid advances in cancer research, the focus of zzso drug development has shifted from zzso chemotherapy to rationally designed agents that target specific molecules associated with zzso cells or their zzso As a consequence of greater public awareness of health related issues and population zzso the detection of early cancer or zzso zzso has demonstrated the potential that exists for targeting the same molecules during zzso One method of such intervention is zzso the zzso zzso or reversal of zzso processes by chemical zzso zzso and zzso have been licensed in the USA for the zzso of breast and zzso zzso respectively in certain zzso zzso zzso zzso Unfortunately, many large-scale cancer zzso trials have yielded negative results, and a few may even have caused harm to healthy individuals considered at risk of developing zzso In this article, the importance of not putting the cart before the horse is zzso In particular, two factors in zzso agent development will be zzso phase zzso studies in patients with cancer or patients at risk of second primary tumors and the validation and incorporation of zzso of zzso from the earliest zzso of clinical zzso This structured approach currently emerging is providing pharmacological and zzso data on novel agents which will prove essential in the planning of zzso zzso 

